← Back to Search

Ophthalmic Solution

VVN539 Ophthalmic Solution 0.02% for Primary Open Angle Glaucoma

Phase 2
Waitlist Available
Research Sponsored by VivaVision Biotech, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8am, 10am, and 4pm at day 7; day 14 and day 21

Summary

This trial is testing VVN539, a medication aimed at lowering eye pressure, in patients with high eye pressure due to POAG or OHT. The medication works by affecting fluid production or drainage in the eye.

Eligible Conditions
  • Primary Open Angle Glaucoma
  • Open-Angle Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8am, 10am, and 4pm at day 7; day 14 and day 21
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8am, 10am, and 4pm at day 7; day 14 and day 21 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Intraocular Pressure
Secondary study objectives
Mean Change in Intraocular Pressure From Baseline

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: VVN539 Ophthalmic Solution 0.02%Active Control1 Intervention
VVN539 Ophthalmic Solution 0.02%
Group II: VVN539 Ophthalmic Solution 0.04%Active Control1 Intervention
VVN539 Ophthalmic Solution 0.04%
Group III: VVN539 Ophthalmic Solution VehiclePlacebo Group1 Intervention
VVN539 Ophthalmic Solution Vehicle

Find a Location

Who is running the clinical trial?

VivaVision Biotech, IncLead Sponsor
4 Previous Clinical Trials
1,080 Total Patients Enrolled
Xiao-Yan Li, M.D.Study DirectorVivaVision
~20 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top